Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma

PURPOSE: The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be potential advantages including tumor downstaging. Th...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Cowey, C. Lance, Amin, Chirag, Pruthi, Raj S., Wallen, Eric M., Nielsen, Matthew E., Grigson, Gayle, Watkins, Cathy, Nance, Keith V., Crane, Jeffrey, Jalkut, Mark, Moore, Dominic T., Kim, William Y., Godley, Paul A., Whang, Young E., Fielding, Julia R., Rathmell, W. Kimryn
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2010
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4525128/
https://ncbi.nlm.nih.gov/pubmed/20159822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.7759
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg